{"filing":{"accession_number":"0001193125-26-347911","cik":"0001782223","ticker":"PYXS","company_name":"Pyxis Oncology, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"pyxs-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526347911/pyxs-20260813.htm"},"events":[{"id":27518,"run_id":25088,"accession_number":"0001193125-26-347911","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses Pyxis Oncology's financial results for the quarter ended June 30, 2026, including detailed condensed consolidated statements of operations and balance sheets. The press release (Exhibit 99.1) announces Q2 2026 financial results with specific metrics: net loss of $25.3 million ($0.40 per share), R\u0026D expenses of $16.1 million, and cash position of $34.5 million as of June 30, 2026. This is a standard quarterly earnings disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.","company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29095,"accession_number":"0001193125-26-347911","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Pyxis Oncology's financial results for the quarter ended June 30, 2026, including detailed condensed consolidated statements of operations and balance sheets. The press release (Exhibit 99.1) announces Q2 2026 financial results with specific metrics: net loss of $25.3 million ($0.40 per share), R\u0026D expenses of $16.1 million, and cash position of $34.5 million as of June 30, 2026. This is a standard quarterly earnings disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:43:37.382474+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29095,"accession_number":"0001193125-26-347911","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Pyxis Oncology's financial results for the quarter ended June 30, 2026, including detailed condensed consolidated statements of operations and balance sheets. The press release (Exhibit 99.1) announces Q2 2026 financial results with specific metrics: net loss of $25.3 million ($0.40 per share), R\u0026D expenses of $16.1 million, and cash position of $34.5 million as of June 30, 2026. This is a standard quarterly earnings disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:43:37.382474+00:00","company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","filing_date":"2026-08-13"}]}